Usefulness of studies on the molecular mechanism of action of herbals/botanicals: The case of St. John's wort

Journal of Biochemical and Molecular Toxicology

Volumn 19, Issue 1, 2005, Pages 1-11

  Choudhuri, Supratim ^a   Valeria Jr , Luis G ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

CYP3A4; Herbal Botanical; Hyperforin; Hypericin; MDR1; Molecular Mechanism; P Glycoprotein (P gp); PXR; Safety; St. John's Wort

Indexed keywords

16ALPHA CYANOPREGNENOLONE; CLOTRIMAZOLE; CYCLOSPORIN; CYTOCHROME P450 3A4; DEXAMETHASONE; DIGOXIN; HYDANTOIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPERFORIN; HYPERICIN; HYPERICUM PERFORATUM EXTRACT; HYPOCHOLESTEROLEMIC AGENT; LITHOCHOLIC ACID; MACROLIDE; MEVINOLIN; MIFEPRISTONE; NIFEDIPINE; PACLITAXEL; PHENOBARBITAL; PLACEBO; PREGNANE X RECEPTOR; RIFAMPICIN; RITONAVIR; SPIRONOLACTONE; SR 12813; TACROLIMUS; TAMOXIFEN; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALERIAN;

CLINICAL TRIAL; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG INDICATION; DRUG INFUSION; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; ENZYME INDUCTION; ENZYME MECHANISM; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; HERBAL MEDICINE; HUMAN; HYPERICUM PERFORATUM; META ANALYSIS; MOLECULAR MECHANICS; NONHUMAN; PROTEIN FUNCTION; PSYCHOPHARMACOLOGY; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW;

ANIMALS; HUMANS; HYPERICUM; PHYTOTHERAPY; PLANT EXTRACTS; PLANTS, MEDICINAL; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID;

HYPERICUM PERFORATUM;

EID: 14644387614     PISSN: 10956670     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbt.20057     Document Type: Review

References (78)

1. Barnes P, Powell-Griner E, McFann K, Nahin R. CDC Advance Data Report #343. Complementary and Alternative Medicine Use Among Adults: United States, 2002. May 27, 2004.
2. Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM, Collins JR, Kliewer SA. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 2000;97:7500-7502.
3. Yin Z-Q, Wang Y, Ye, W-C, Zhao, S-X. Chemical constituents of Hypericum perforatum (St. John's wort) growing in China. Biochem Syst Ecol 2004;32:521-523.
4. Bombardelli E and Morazzoni P. Hypericum perforatum. Fitoterapia 1995;66:43-68.
5. Newall C, Anderson LA, Phillipson JD. St. John's wort. In: Herbal Medicines. London: Pharmaceutical Press; 1996. 250 pp.
6. Upton R. St. John's wort, Hypericum perforatum: Quality control, analytical and therapeutic monograph. American Herbal Pharmacopoeia and Therapeutic Compendium. Santa Cruz, CA: American Herbal Pharmacopoeia; 1997.
7. Greeson JM, Sanford B, Monti DA. St. John's wort (Hypericum perforatum): A review of the current pharmacological, toxicological, and clinical literature. Psychopharmacology 2001;153:402-414.
8. Nahrstedt A, Butterweck V. Biologically active and other chemical constituents of the herb of Hypericum perforatum L. Pharmacopsychiatry. 1997;30 (Suppl 2):129-134.
9. Bergonzi MC, Bilia AR, Gallori S, Guerrini D, Vincieri FF. Variability in the content of the constituents of Hypericum perforatum L. and some commercial extracts. Drug Dev Ind Pharm 2001;27:491-497.
10. Wagner H, Bladt S. Pharmaceutical quality of hypericum extracts. J Geriatr Psychiatry Neurol 1994;7(Suppl 1):S65-S68.
11. Kopleman SH, NguyenPho A, Zito WS, Muller FX, Augsburger LL. Selected physical and chemical properties of commercial Hypericum perforatum extracts relevant for formulated product quality and performance. AAPS PharmSci. 2001;3:E26.
12. Verotta L, Appendino G, Belloro E, Jakupovic J, Bombardelli E. Furohyperforin, a prenylated phloroglucinol from St. John's wort (Hypericum perforatum). J Nat Prod 1999;62:770-772.
13. Verotta L, Appendino G, Jakupovic J, Bombardelli E. Hyperforin analogues from St. John's wort (Hypericum perforatum). J Nat Prod 2000;63:412-415.
14. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St. John's wort for depression - An overview and meta-analysis of randomised clinical trials. Br Med J 1996;313:253-258.
15. Blumenthal M. St. John's wort. In: Busse WR, Goldberg A, Gruenwalk J, Hall T, Riggins CW, Rister RS, editors. The complete German Commission E monographs. Therapeutic guide to herbal medicines. Boston, MA: Integrative Medicine Communications; 1998. pp 214-215.
16. WHO monographs on selected medicinal plants. Herba Hyperici. Geneva: WHO; 2001. Vol. 2, pp. 149-171.
17. Hahn G. Hypericum perforatum (St. John's wort) - A medicinal herb used in antiquity and still of interest today. J Naturopathic Med 1992;3:94-96.
18. Bisset NG, Wichtl, M. Herbal drugs and phytopharmaceuticals: A handbook for practice on a scientific basis. New York: CRC Press, 1994. p. 566.
19. Ernst E. SJW, an anti-depressant? A systematic, criteria-based review. Phytomed 1995;2:67-71.
20. Volz HP. Controlled clinical trials of hypericum extracts in depressed patients - An overview. Pharmacopsychiatry 1997;30(Suppl 2):72-76.
21. Mahady GB, Fong HHS, Farnsworth NR. Botanical dietary supplements: Quality, safety and efficacy. In Botanical dietary supplements: Quality, safety and efficacy. Mahady GB, Fong, HHS, Farnsworth NR, editors, Ca Lisse: Swets & Zeitlinger; 2001. 271 pp.
22. Schilcher H. Phytotherapy in pediatrics - Handbook for physicians and pharmacists. Stuttgart: Medpharm Scientific; 1997. pp. 61-62.
23. nd edition, New York: Wiley; 2003. 688 pp.
24. Stevinson C, Ernst E. Hypericum for depression. An update of the clinical evidence. Eur Neuropsychopharmacol 1999;9:501-505.
25. Nangia M, Syed W, Doraiswamy PM. Efficacy and safety of St. John's wort for the treatment of major depression. Public Health Nutr 2000;3:487-494.
26. Bilia AR, Gallori S, Vincieri FF. St. John's wort and depression: Efficacy, safety and tolerability - An update. Life Sci 2002;70:3077-3096.
27. Rodriguez-Landa JF, Contreras CM. A review of clinical and experimental observations about anti-depressant actions and side effects produced by Hypericum perforatum extracts. Phytomedicine 2003;10:688-699.
28. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St. John's wort) in major depressive disorder: A randomized controlled trial. JAMA 2002;287:1807-1814.
29. Shelton RC, Keller MB, Gelenberg A, Dunner DL, Hirschfeld R, Thase ME, Russell J, Lydiard RB, Crits-Cristoph P, Gallop R, Todd L, Hellerstein D, Goodnick P, Keitner G, Stahl SM, Halbreich U. Effectiveness of St. John's wort in major depression: A randomized controlled trial. JAMA 2001;285:1978-1986.
30. Perovic S, Muller WE. Pharmacological profile of hypericum extract. Effect on serotonin uptake by postsynaptic receptors. Arzneimittelforschung 1995;45:1145-1148.
31. Muller WE, Singer A, Wonnemann M, Hafner U, Rolli M, Schafer C. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacopsychiatry 1998;31(Suppl 1):16-21.
32. Franklin M, Chi J, McGavin C, Hockney R, Reed A, Campling G, Whale RW, Cowen PJ. Neuroendocrine evidence for dopaminergic actions of hypericum extract (LI 160) in healthy volunteers. Biol Psychiatry 1999;46:581-584.
33. Mennini T, Gobbi M. The anti-depressant mechanism of Hypericum perforatum. Life Sci 2004;75:1021-1027.
34. Thiele B, Brink I, Ploch M. Modulation of cytokine expression by hypericum extract. J Geriatr Psychiatry Neurol 1994;7(Suppl 1):S60-S62.
35. Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, Jones SA, McKee DD, Oliver BB, Willson TM, Zetterstrom RH, Perlmann T, Lehmann JM. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 1998;92:73-82.
36. Bertilsson G, Heidrich J, Svensson K, Asman M, Jendeberg L, Sydow-Backman M, Ohlsson R, Postlind H, Blomquist P, Berkenstam A. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci USA 1998;95:12208-122013.
37. Blumberg B, Sabbagh W. Jr, Juguilon H, Bolado J. Jr, van Meter CM, Ong ES, Evans RM. SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev 1998;12:3195-3205.
38. Xie W, Barwick JL, Downes M, Blumberg B, Simon CM, Nelson MC, Neuschwander-Tetri BA, Brunt EM, Guzelian PS, Evans RM. Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 2000;406:435-439.
39. Goodwin B, Redinbo MR, Kliewer SA. Regulation of CYP3A gene transcription by the pregnane X receptor. Annu Rev Pharmacol 2002;42:1-23.
40. Watkins RE, Wisely GB, Moore LB, Collins JL, Lambert MH, Williams SP, Willson TM, Kliewer SA, Redinbo MR. The human nuclear xenobiotic receptor PXR: Structural determinants of directed promiscuity. Science 2001;292:2329-2333.
41. Kobayashi K, Yamagami S, Higuchi T, Hosokawa M, Chiba K. Key structural features of ligands for activation of human pregnane X receptor. Drug Metab Dispos 2004;32:468-472.
42. Kliewer SA, Goodwin B, Willson TM. The nuclear pregnane X receptor: A key regulator of xenobiotic metabolism. Endocrine Rev 2002;23:687-702.
43. Kliewer SA, Willson TM. Regulation of xenobiotic and bile acid metabolism by the nuclear pregnane X receptor. J Lipid Res 2002;43:359-364.
44. Watkins RE, Maglich JM, Moore LB, Wisely GB, Noble SM, Davis-Searles PR, Lambert MH, Kliewer SA, Redinbo MR. 2.1 A crystal structure of human PXR in complex with the St. John's wort compound hyperforin. Biochemistry 2003;42:1430-1438.
45. Matheny CJ, Ali RY, Yang X, Pollack GM. Effect of prototypical inducing agents on P-glycoprotein and CYP3A expression in mouse tissues. Drug Metab Dispos 2004;32:1008-1014.
46. Shibata H, Spencer TE, Onate SA, Jenster G, Tsai SY, Tsai M, O'Malley BW. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. Recent Prog Horm Res 1997;52:141-164.
47. Sheppard HM, Harries JC, Hussain S, Bevan C, Heery DM. Analysis of the steroid receptor coactivator 1 (SRC1)-CREB binding protein interaction interface and its importance for the function of SRC1. Mol Cell Biol 2001;21:39-50.
48. Kliewer SA. The nuclear pregnane X receptor regulates xenobiotic detoxification. J Nutr 2003;133:2444S-2447S.
49. Takeshita A, Taguchi M, Koibuchi N, Ozawa Y. Putative role of orphan nuclear receptor SXR (steroid and xenobiotic receptor) in the mechanism of CYP3A4 inhibition by xenobiotics. J Biol Chem 2002;277:32453-32458.
50. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998;102:1016-1023.
51. Jones SA, Moore LB, Shenk JL, Wisely GB, Hamilton GA, McKee DD, Tomkinson NC, LeCluyse EL, Lambert MH, Willson TM, Kliewer SA, Moore JT. The pregnane X receptor: A promiscuous xenobiotic receptor that has diverged during evolution. Mol Endocrinol 2000;14:27-39.
52. Dussault I, Lin M, Hollister K, Wang EH, Synold TW, Forman BM. Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR. J Biol Chem 2001;276:33309-33312.
53. Maurel P. The CYP3A family. In: Ioannides C. editor, Cytochromes P450: Metabolic and toxicological aspects. Boca Raton, FL: CRC Press; 1996. pp. 241-270.
54. Staudinger JL, Goodwin B, Jones SA, Hawkins-Brown D, MacKenzie KI, LaTour A, Liu Y, Klaassen CD, Brown KK, Reinhard J, Willson TM, Koller BH, Kliewer SA. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci USA 2001;98:3369-3374.
55. Pascussi JM, Gerbal-Chaloin S, Drocourt L, Maurel P, Vilarem MJ. The expression of CYP2B6, CYP2C9, and CYP3A4 genes: A tangle of networks of nuclear and steroid receptors. Biochim Biophys Acta 2003;1619:243-253.
56. Bertilsson G, Berkenstam A, Blomquist P. Functionally conserved xenobiotic responsive enhancer in cytochrome P450 3A7. Biochem Biophys Res Commun 2001;280:139-244.
57. Goodwin B, Moore LB, Stoltz CM, McKee DD, Kliewer SA. Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol Pharmacol 2001;60:427-431.
58. Maglich JM, Stoltz CM, Goodwin B, Hawkins-Brown D, Moore JT, Kliewer SA. Nuclear pregnane X receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol Pharmacol 2002;62:638-646.
59. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 2001;276:14581-14587.
60. Kast HR, Goodwin B, Tarr PT, Jones SA, Anisfeld AM, Stoltz CM, Tontonoz P, Kliewer S, Willson TM, Edwards PA. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 2002;277:2908-2915.
61. Biber A, Fischer H, Romer A, Chatterjee SS. Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteers. Pharmacopsychiatry 1998;31(Suppl 1):36-43.
62. Cantoni L, Rozio M, Mangolini A, Hauri L, Caccia S. Hyperforin contributes to the hepatic CYP3A-inducing effect of Hypericum perforatum extract in the mouse. Toxicol Sci 2003;75:25-30.
63. Dürr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K. St. John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000;68:598-604.
64. Sugimoto K, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada K, Arakawa M, Sakamoto K, Masada M, Miyamori I, Fujimura A. Different effects of St. John's wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 2001;70:518-524.
65. Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR. Drug interaction between St. John's wort and cyclosporine. Ann Pharmacotherap 2000;34:1013-1016.
66. Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G. Acute heart transplant rejection due to St. John's wort. Lancet 2000;355:548-549.
67. Mai I, Stormer E, Bauer S, Kruger H, Budde K, Roots I. Impact of St. John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant 2003;18:819-822.
68. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St. John's wort. Lancet 2000;355:547-548.
69. de Maat MM, Hoetelmans RM, Mathot RA, van Gorp EC, Meenhorst PL, Mulder JW, Beijnen JH. Drug interaction between St. John's wort and nevirapine. AIDS 2001;15:420-421.
70. Johne A, Schmider J, Brockmoller J, Stadelmann AM, Stormer E, Bauer S, Scholler G, Langheinrich M, Roots I. Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort (Hypericum perforatum). J Clin Psychopharmacol 2002;22:46-54.
71. Wang Z, Hamman MA, Huang SM, Lesko LJ, Hall SD. Effect of St. John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 2002;71:414-420.
72. Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St. John's wort (Hypericum perforatum). Clin Pharmacol Ther 1999;66:338-345.
73. Markowitz JS, Donovan JL, DeVane CL, Taylor RM, Ruan Y, Wang JS, Chavin KD. Effect of St. John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003;290:1500-1504.
74. Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 2003;42:1141-1160.
75. Hennessy M, Kelleher D, Spiers JP, Barry M, Kavanagh P, Back D, Mulcahy F, Feely J. St. Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol 2002;53:75-82.
76. Nebel A, Schneider BJ, Baker RK, Kroll DJ. Potential metabolic interaction between St. John's wort and theophylline. Ann Pharmacother 1999;33:502.
77. Wenk M, Todesco L, Krahenbuhl S. Effect of St. John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females. Br J Clin Pharmacol 2004;57:495-499.
78. Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P. St. John's wort (Hypericum perforatum): Drug interactions and clinical outcomes. Br J Clin Pharmacol 2002;54:349-356.